Recently, Pfizer Inc (NYSE:PFE) disclosed their third quarter results which provided results and reports related to third quarter reports and performance of the company. Moreover, forward looking statements were discussed at the time of disclosure of the third quarter report. There were also various things which were discussed in Pfizer’s 2012 annual report on the form 10 – K and Form 10 – Q and 8 – K. Also some of the certain financial measures were discussed at the time of disclosure of the report.
According to management of the organization, they managed to deliver a good operational performance there by generating solid financial results and continue to provide a steady progress with the help of on line products and other pipeline assets.
Talking about the operational revenues of the company, the Oncology business of the organization grew by 26% with the help of the availability of the new and continued strong performance of new products. These products include Xalkori and Inlyta. Also another strong quarter was made available with the help of operation of Lyrica which grew by 11% and from Celebrex which helped in growing by 13%.
Despite of the Macro Economic factors, the emerging market business also grew by 5% on operational basis. Turning to the recent launched approved pipeline and product assets, the company received FDA approval of Duavee which is a combination of therapy for the treatment of moderate to severe vasomotor symptoms that are associated with prevention of postmenopausal osteoporosis and menopause. This product has received a lot of anticipation and appreciation from the people of United States of America during the first quarter of the company.
With time, positive momentum has been received by the people and also a direct to consumer television advertising campaign is being planned to be launched by the management of the company.
